Healthcare Global Enterprises Ltd. · NSE:HCG
Healthcare Global Enterprises — Q1 FY2027 Earnings Presentation
28 slides from Healthcare Global Enterprises's earnings presentation, Aug 6, 2026
Slide 1: Exchange filing cover letter for Investor Presentation
Dear Sir/Madam, National Stock Exchange of India Limited, BSE Limited, Compliance Department, Compliance Department, Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai - 400051, Dalal Street, Mumbai - 400001, Maharashtra, India Maharashtra, India Subject : Investo
Slide 2: Q1 FY2027 Results Presentation
HEALTHCARE GLOBAL ENTERPRISES LIMITED Q1 FY2027 Results Presentation August 6, 2026
Slide 3: Safe Harbor
Safe Harbor This presentation and its contents are confidential and are not for release, publication or distribution, in whole or in part, directly or indirectly, in or into or from the United States of America, Canada, Australia, Japan or any jurisdiction where such distribution is unlawful. This p
Slide 4: Strategic Progress Over the Past Year
Strategic Progress Over the Past Year Executing Our Strategy | Building the Foundation for Sustainable Long-Term Value Creation Focus on core oncology Capacity expansion Capital strength Completed Strategic Exit from Milann North Bengaluru Hospital Operational Successfully Completed Rights Iss
Slide 5: Q1 FY27: Performance Update
Q1 FY27: Performance Update Q1 FY27: Performance Update Revenue grew 13% y-o-y, while Adjusted EBITDA grew 20% y-o-y, with margins improving to 19.4% compared to 18.2% in Q1 FY26 Financial Highlights 6,951 Mn 1,223 Mn 1,339 Mn 138 Mn Revenue Reported EBITDA Adjusted EBITDA1 Profit after Tax2 Margins
Slide 6: HCG Key Highlights: Q1 FY27
HCG Key Highlights: Q1 FY27 HCG Key Highlights: Q1 FY27 HCG delivered revenue of INR 6,951 Mn in Q1FY27, reflecting ~13% YoY growth • Broad-based growth continued across clusters in Q1FY27. Revenue growth was led by volume growth of 11% y-o-y. ARPP grew by 2%, improvement driven by a favourable payo
Slide 7: Financial Highlights: Q1 FY27
Financial Highlights: Q1 FY27 Financial Highlights: Q1 FY27 Overall Revenue Adjusted EBITDA1 Volumes (excl. Fertility)2 Margin (%) 18.2% 19.4% +13% +20% +11% 6,951 78,914 6,132 1,339 71,095 1,118 Q1FY26 Q1FY27 Q1FY26 Q1FY27 Q1FY26 Q1FY27 Revenue (excl. Fertility)2 Adjusted EBITDA1 (excl. Fertility)2
Slide 8: Revenue Mix By Specialty and Payor: Q1 FY27
Revenue Mix By Specialty and Payor: Q1 FY27 Specialty Mix Trend Payor Mix : Increasing Share of Cash & TPA Business in Line with Stated Strategy Non 13% 12% 12% 11% Government Oncology 34% 33% 33% 31% 16% 16% 16% 15% OP + Other services Medical Value 2% 2% 3% 19% 21% 3% Travel 20% 20% Surgical 25% 2
Slide 9: Region-wise Performance Update: South
Region-wise Performance Update: South Revenue Share % +16% Vizag Q1 40% 2,607 2,765 Revenue 2,384 Gulburga Vijaywada FY27 (INR Mn) Hubli Ongole Shimonga Bangalore Bed Share1 % Q1FY26 Q4FY26 Q1FY27 Chennai Q1 45% +7% FY27 Overall 30,737 31,723 32,915 Volumes Q1 FY27 (# of IP Patients) # of Centres To
Slide 10: Region-wise Performance Update: West
Region-wise Performance Update: West Revenue Share % +9% 2,752 2,865 3,010 Jaipur Q1 43% Revenue FY27 (INR Mn) Indore Rajkot Ahmedabad Baroda Nagpur Bed Share1 % Bhavnagar Nashik Q1FY26 Q4FY26 Q1FY27 Mumbai Q1 42% +10% FY27 Overall 28,840 30,249 31,789 Volumes Q1 FY27 (# of IP Patients) # of Centres
Slide 11: Region-wise Performance Update: East
Region-wise Performance Update: East Revenue Share % +22% 11% 799 Q1 656 699 Revenue FY27 (INR mn) Ranchi Kolkata Bed Share1 % Cuttack Q1FY26 Q4FY26 Q1FY27 12% Q1 +25% FY27 11,095 12,296 Overall 9,800 Volumes Q1 FY27 (# of IP Patients) # of Centres Total Operating Beds # of LINACs Q1FY26 Q4FY26 Q1FY
Slide 12: HCG: Growth Plans and Strategic Priorities
HCG: Growth Plans and Strategic Priorities 11 www.hcgoncology.com www. h c g o n c o l o g y. c o m
Slide 13: Bed Addition: 1,000 beds by FY30, led by brownfield expansion
Bed Addition: 1,000 beds by FY30, led by 60% brownfield expansion 31st Mar’26 FY27 FY28 & FY29 FY30 FY30 P 2,734 188 Bed addition ~520 Bed addition ~230 Bed addition ~3,670 Capex ~INR 1,500 Mn Capex ~INR 3,000 Mn Capex ~INR 1,000 Mn No. of Operational Beds¹ 92 96 ~180 ~340 ~100 ~130 Greenfield: Nort
Slide 14: Strategic Priorities To Accelerate Long-Term Value Creation
Strategic Priorities To Accelerate Long -Term Value Creation A B C D Optimize Existing Improve Network Enhance Patient Invest in Growth Network Efficiency Experience 1. Build best-in-class talent → 1. Undertake prudent cost 1. Brownfield expansion across 1. Invest in upgrading existing improve case
Slide 15: Q1FY27 Consolidated Profit & Loss
Q1FY27 Consolidated Profit Loss Q1FY27 Consolidated Profit & Loss Profit and Loss (INR in Mn.) Q1FY27 Q1FY26 Y-o-Y Q4FY26 Revenues from Operations 6,933.9 6,118.0 6,502.9 Income from Govt. Grant 17.1 13.6 20.4 Total Revenue from Operations 6,951.0 6,131.6 13.4% 6,523.3 Cost of Goods Sold 1,788.0 1,6
Slide 16: Q1FY27 Operational Metrics
Q1FY27 Operational Metrics Key Metrics South West East Consolidated1 Q4FY26 Q1FY27 Q4FY26 Q1FY27 Q4FY26 Q1FY27 Q4FY26 Q1FY27 Bed Capacity 1,343 1,483 1,440 1,440 333 359 3,131 3,304 Operational Beds 1,238 1,299 1,163 1,190 318 344 2,734 2,855 Census Beds2 942 991 1,066 1,093 310 334 2,333 2,440 In-P
Slide 17: HCG: India's Leading Oncology Platform
HCG: India’s Leading Oncology Platform 16 www.hcgoncology.com www. h c g o n c o l o g y. c o m
Slide 18: A Unique Oncology Platform Redefining Comprehensive Cancer Care Treatment
A Unique Oncology Platform Redefining Comprehensive Cancer Care Treatment A Unique Oncology Platform Redefining Comprehensive Cancer Care Treatment Largest oncology-focused hospital chain Focused approach and with a pan-India network 1 4 Tumor Board enabling effective cancer care Preferred destinati
Slide 19: Largest Pan-India Oncology Focused Hospital Chain
1. Largest Pan-India Oncology Focused Hospital Chain 1. Largest Pan -India Oncology Focused Hospital Chain Largest Geographical Reach… 19 /10 26 Number of Cities and No. of states covered1 hospitals3 Jaipur 3k+ 16/19 Ahmedabad Capacity Leading Indore Ranchi Kolkata beds3 positions2 Rajkot Baroda Bha
Slide 20: Preferred Platform for Leading Oncology Specialists
2. Preferred Platform for Leading Oncology Specialists Integrated Oncology Ecosystem Focused Specialty with Scale Clinical Excellence and Academics Integrated Medical, Full time and exclusive Oncology-specific Access to cutting-edge High degree of clinical Surgical & Radiation Strong referral networ
Slide 21: Introducing Latest Medical Technology in Cancer Care
3. Introducing Latest Medical Technology in Cancer Care TRACK RECORD OF BEING 1st TO LAUNCH ADVANCED State-of-the-art Equipment in each modality TECHNOLOGY IN INDIA Total PET CTs : 20 DIAGNOSTICS 2026 MR-LINAC1 AI- based 2022 RIS PACS Digital PET Digital CT Automated Digital Skyra Tesla 3T Molecular
Slide 22: Tumor Board Approach to Deliver Customized Treatment
4. Tumor Board Approach to Deliver Customized Treatment 4. Tumor Board Approach to Deliver Customized Treatment Spearheaded by Dr. Ajai, who also heads IRC1 of 30+ 17+ years of nation-wide Supplemented by multiple oncologists for Investigator Initiated Research Studies Tumor Boards held weekly local
Slide 23: Leading Destination for Comprehensive Cancer Care
5. A Leading Destination for Comprehensive Cancer Care From Early Diagnosis and Treatment to Survivorship 5. A Le a d ing De s t ina t ion f or C omp r e he nsive C a nc e r C a r e Fr om E a r ly Dia gnosis a nd T r e a t me nt t o Su r v iv orship Diagnostics Treatment Post Care Genomics and Digit
Slide 24: Experienced Board of Directors
6. Experienced Board of Directors 6. Experienced Board of Directors Dr. BS Ajai Kumar Geeta Mathur Founder and Non-Executive Chairman Non-Executive Independent Director Visionary and key driving force of HCG, with an aim to make advanced cancer Experienced finance professional, serving on Boards of
Slide 25: HCG Shareholding Pattern and Key Shareholders
HCG Shareholding Pattern and Key Shareholders Top Institutional Investors as on 30th June 2026 Public 14% Foreign Institutional Investors 3% Promoters 64% 30th June, Domestic 2026 Institutional Investors 19% 24 www.hcgoncology.com * All logos are for representation purpose only and copyright belong
Slide 26: Annexure: Definitions
Annexure: Definitions Key Metrics Definitions Bed Capacity Bed Capacity reflects total beds that can be accommodated in the hospitals Operational / Census Beds Operational beds comprises of Census and non-census beds Census Beds Revenue generating beds including IPD/Ward beds and Chemo beds Non-Cens
Slide 27: About Us
CIN: L15200KA1998PLC023489 About Us: HealthCare Global Enterprises Ltd. For updates and specific queries, please visit www.hcgoncology.com or contact: (HCG), headquartered in Bengaluru, is the largest provider of cancer care in India. Through its network of 26 hospitals across India and Kenya, Healt
Slide 28: Thank You
THANK YOU www.hcgoncology.com www. h c g o n c o l o g y. c o m
HealthCare Global Enterprises — Q1 FY2027 Earnings Presentation on 6ix